Author: Patric Stafshede

Omnio receives award for strong growth

Omnio has been identified as the fastest growing SME (revenues 5-500 million SEK) in the county of Västerbotten in 2016. […]
read more

Prometic receives clearance for phase 2 clinical trial

Omnio’s licensee Prometic Life Sciences (TSX:PLI) has announced that they have received approval from the Swedish Medical Products Agency (Läkemedelsverket) […]
read more

Tor Ny awarded Erling-Persson research grant

Professor Tor Ny, founder of Omnio, has been awarded €600 k from the Erling-Persson Family Foundation to continue basic research relating to […]
read more

New co-workers needed! // Omnio rekryterar!

Do you want to work with development of a protein drug in Umeå? Omnio is expanding, and is recruiting talent […]
read more

Changes in Omnio leadership

Omnio’s founder, professor Tor Ny, is stepping down from the position of CEO in order to focus on the scientific […]
read more

Strategic license deal with ProMetic Life Sciences

UMEÅ, SWEDEN – November 12, 2015 – Omnio AB (www.omnio.se) announced today that it has entered into a strategic research […]
read more